MBIO
Mustang Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.54
−3.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | 41.0K | — | 2.2M | 3.0M |
| Gross Profit | — | (41.0K) | — | (2.2M) | (3.0M) |
| Operating Expenses | |||||
| R&D Expense | 418.0K | 1.5M | 8.4M | 39.2M | 63.9M |
| SG&A Expense | 3.8M | 3.9M | 4.1M | 9.3M | 12.2M |
| General & Admin Expense | 3.8M | 3.9M | 4.1M | 9.7M | 12.2M |
| Selling & Marketing Expense | — | — | — | (365.0K) | — |
| Other Expenses | (666.0K) | (3.1M) | 3.7M | — | (3.0M) |
| Total Operating Expenses | 3.5M | 2.4M | 16.2M | 48.5M | 73.1M |
| Cost and Expenses | 3.5M | 2.4M | 16.2M | 50.7M | 76.2M |
| Operating Income (EBIT) | (3.5M) | (2.4M) | (16.2M) | (50.7M) | (76.2M) |
| Non-Operating | |||||
| Interest Income | 489.0K | 511.0K | 184.0K | 850.0K | 689.0K |
| Interest Expense | — | — | (5.0K) | 1.3M | 3.4M |
| Net Interest Income | 489.0K | 511.0K | 189.0K | (464.0K) | (2.7M) |
| Other Non-Op Income/Expense | 489.0K | 511.0K | 493.0K | (876.0K) | (1.4M) |
| Non-Operating Income (excl Interest) | (489.0K) | (511.0K) | (498.0K) | (438.0K) | (2.0M) |
| EBT (Pre-Tax Income) | (3.0M) | (1.9M) | (15.8M) | (51.6M) | (77.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (3.0M) | (1.9M) | (15.8M) | (51.6M) | (77.5M) |
| Earnings from Cont. Ops | (3.0M) | (1.9M) | (15.8M) | (51.6M) | (77.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.0M) | (1.9M) | (15.8M) | (51.6M) | (77.5M) |
| Per Share | |||||
| Basic EPS | ($0.45) | ($0.39) | ($2.57) | ($6.00) | ($11.25) |
| Diluted EPS | ($0.45) | ($0.39) | ($2.57) | ($6.00) | ($11.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.7M | 4.9M | 6.1M | 8.6M | 6.9M |
| Diluted Shares Outstanding | 6.7M | 4.9M | 6.1M | 8.6M | 6.9M |
| Profitability Metrics | |||||
| EBITDA | (3.0M) | (1.9M) | (14.9M) | (48.1M) | (71.1M) |
| D&A | — | 41.0K | 823.0K | 2.2M | 3.0M |
| EBIT | (3.0M) | (1.9M) | (15.7M) | (50.3M) | (74.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026